SynthesisTargeted oncology2018

Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis.

Elvira Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.